Lead Product(s) : Elocalcitol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Adge Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Adge has secured a global license to RO269228, a clinical stage oral small molecule originally developed by Roche for osteoporosis. RO269228, also known as elocalcitol, is a vitamin D analog which has demonstrated efficacy and safety in multiple Phase 2 ...
Product Name : RO269228
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
April 25, 2022
Lead Product(s) : Elocalcitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Adge Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Ribitol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Details : 43% increase in ratio of glycosylated alpha-dystroglycan to total αDG from baseline were measured for BBP-418, across all three dosing cohorts, signifying the oral therapy has potential to address both the root cause of LGMD2i and drive functional impro...
Product Name : BBP-418
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2022
Lead Product(s) : Ribitol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable